In line with our strategy to expand our global leadership in cosmetics and personal care and to diversify our clinical testing footprint in dermatology, for medicinal products and medical devices, Eurofins announces that it has successfully completed acquisition of bioskin GmbH (“bioskin”) a full-service, dermatology-specific CRO specializing in trials for drugs, medical devices, food supplements and advanced cosmetics.
This acquisition, providing a range of complementary and extended services, supports Eurofins’ continued growth plans in these markets and further strengthens our offering to our customers and facilitates their one-stop access to multi-centric studies.
The company will hereafter be referred to as “Eurofins bioskin”.
Eurofins announces their acquisition of Alba Science as part of its long-term strategy to expand and strengthen its capabilities in cosmetics and personal care testing.
Today, we cater to an increasing demand for clinical studies by adapting our approach to expansion through acquisitions, strategic partnerships, and investments.
Eurofins’s recent acquisition supports the 2021 strategy in multiple ways: expanding upon existing capabilities, enabling us to offer more clinical studies, insight and sensory evaluation, opening access to a significant UK panelists database and custom imaging system, and bringing us closer to local and regional customers. The Scottish company headquartered in Edinburgh and employs 23 people.
This acquisition will further assert our leadership position in the cosmetic testing market globally.
The company will hereafter be referred to as “Eurofins Alba”.
Sorry, the comment form is closed at this time.